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Background  and  purpose:  There  were  limited  data  about  comparison  of  zotarolimus-eluting  stents  (ZES)
and everolimus-eluting  stents  (EES)  in  patients  with  small  coronary  artery  disease  (CAD),  especially  in
patients with  acute  myocardial  infarction  (AMI).  The  objective  of  this  study  was  to compare  the clinical
outcomes  of ZES  and  EES  in  patients  with  AMI for small  CAD.
Methods  and  subjects:  A  total  1565  AMI patients  treated  with  Endeavor-ZES  (n = 651)  (Medtronic  Cardio-
Vascular,  Santa  Rosa,  CA,  USA)  or Xience  V/Promus-EES  (n = 914) (Abbott  Vascular,  Temecula,  CA/Boston
Scientiﬁc,  Natick,  MA,  USA)  for small  CAD  (stent  diameter  ≤2.75  mm)  in KAMIR  (Korea  Acute  Myocardial
Infarction  Registry)  were  enrolled.  After  propensity  score  matching  to adjust  for baseline  clinical  and  angi-
ographic  characteristics,  we compared  a total  1302  patients  (651 ZES and  651  EES)  about  major  adverse
cardiac  events  (MACE)  at  1-year.  Subgroup  analysis  about  1-year  clinical  outcomes  was  undertaken  in
patients who  were  discharged  alive.
Results:  Baseline  clinical  and  angiographic  characteristics  were  similar  between  the  two  groups  after
propensity  score  matching.  Total  MACE  did not  differ  between  the  two  groups  before  (9.8%  vs. 8.2%,
p  =  0.265)  and  after  (9.8%  vs. 9.4%,  p =  0.778)  propensity  score  matching.  The  EES  group  showed  lower
rate  of 1-year  cardiac  death  (5.4%  vs.  3.3%,  p  = 0.041),  target  lesion  failure  (TLF;  6.9% vs. 4.3%,  p =  0.022),
and  stent  thrombosis  (1.4%  vs. 0.4%,  p  = 0.042) compared  with  the  ZES  group.  However,  there  were  no
differences  in 1-year  cardiac  death,  TLF,  and stent  thrombosis  in propensity  score  matched  populations.
Other  various  1-year  clinical  outcomes  showed  no  difference  between  the  two groups.  Subgroup  analysis
in patients  who  were  discharged  alive  showed  similar  outcomes  between  the  two  groups  at 1-year  follow-
up.
Conclusion:  In-this  propensity  score  matched  analysis,  EES  and  ZES showed  no signiﬁcant  difference  in
clinical  outcomes  at 1-year  follow-up  in  patients  with  AMI  for small  CAD.
©  2∗ Corresponding author at: Chonnam National University Hospital, 42 Jaebong-ro,
ong-gu, Gwangju 501-757, Republic of Korea. Tel.: +82 62 220 6243;
ax: +82 62 228 7174.
E-mail addresses: myungho@chollian.net, myungho@chol.com (M.H. Jeong).
914-5087/$ – see front matter © 2013 Published by Elsevier Ltd on behalf of Japanese Co
ttp://dx.doi.org/10.1016/j.jjcc.2013.10.016013  Published  by  Elsevier  Ltd on  behalf  of Japanese  College  of Cardiology.
Introduction
Primary percutaneous coronary intervention (PCI) has become
a gold standard treatment strategy in acute myocardial infarc-
tion (AMI) [1]. The efﬁcacy of drug-eluting stents (DES) have been
proved to be effective in reducing in-stent restenosis (ISR) and
target-vessel revascularization (TVR) without an increase in any
safety outcomes [2,3]. We had reported the efﬁcacy and safety of
llege of Cardiology.
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ES in patients with AMI  who were enrolled in the KAMIR-registry
Korea Acute Myocardial Infarction Registry). According to KAMIR
ata, DES can be used safely and effectively to treat AMI  patients by
educing the need for repeat revascularizations and by not increas-
ng the risks of mortality, myocardial infarction (MI), and stent
hrombosis [4].
In ischemic heart disease, DES implantation switched over
rom the ﬁrst generation to second generation resulted in less
VR and stent thrombosis [5] because the second-generation DES,
he zotarolimus-eluting stent (ZES) and the everolimus-eluting
tent (EES) had reported excellent results for clinical outcomes in
oronary artery disease (CAD) [6–8]. DES for small CAD showed
igniﬁcantly lower rate of ISR rate compared with bare metal stent
BMS) despite more severe small CAD lesions in the DES group [9].
mall vessel CAD is associated with higher rates of adverse cardiac
vents [10,11], and is an independent predictor of restenosis and
arget lesion revascularization (TLR) in patients with DES implan-
ation [12–14].
However, there are limited data about direct comparison of ZES
nd EES in small CAD, especially in patients with AMI. Therefore, we
onducted the present study to analyze the clinical efﬁcacy of EES
nd ZES in patients with AMI  for small CAD who were registered in
 large-scale, prospective, multi-center, “real-world” registry – the
AMIR.
ethods
tudy population and KAMIR
The KAMIR is a Korean large-scale, prospective, multi-center,
nd observational online registry that is designed to reﬂect the
real-world” practice in Korean AMI  patients with support from the
orean Circulation Society from November 2005. Online registry
f AMI  (at www.kamir.or.kr) has been performed at 52 university
r community hospitals that are high-volume centers with facili-
ies for primary PCI and onsite cardiac surgery. The study protocol
as approved by the ethics committee at each participating insti-
ution, and all patients were informed about their participation in
he registry.
From January 2008 to October 2011, a total 21,495 consecu-
ive AMI  patients were registered in KAMIR. Among them, 3972
atients underwent PCI for small CAD (stent diameter ≤2.75 mm).
mong them, we enrolled patients with AMI  who were treated with
ndeavor-ZES (Medtronic CardioVascular, Santa Rosa, CA, USA) and
ienceV/Promus-EES (Abbott Vascular, Temecula, CA/Boston Sci-
ntiﬁc, Natick, MA,  USA) and completed 1-year clinical follow-up.
he exclusion criteria of the patients were performing thrombolytic
herapy, plain balloon angioplasty alone, other DES or BMS  implan-
ation, or conservative treatment without PCI. The patients who  had
ontraindication to antithrombotic agents, known bleeding disor-
ers, infarct-related graft vessel, or malignant neoplasm were also
xcluded. Finally, a total 1565 eligible AMI  patients were enrolled.
hese patients were divided into the ZES group (n = 651) and the
ES group (n = 914).
eﬁnitions and clinical follow-up
The diagnosis of AMI  was according to a consensus docu-
ent of the Third Universal Deﬁnition of Myocardial Infarction
y the writing group of behalf of the joint European Society of
ardiology/American College of Cardiology Foundation/American
eart Association/World Heart Federation [15]. Hypertension was
eﬁned as repeated measurement of systolic blood pressure
140 mmHg  and/or diastolic blood pressure >90 mmHg  at rest or
reatment with anti-hypertensive medications. Diabetes mellituslogy 63 (2014) 409–417
was deﬁned as having an established diagnosis of diabetes mellitus
or use of oral hypoglycemic agents or insulin. Hyperlipidemia was
deﬁned as a total cholesterol level >200 mg/dL or treatment with
a lipid-lowering agent. Prior ischemic heart disease was  deﬁned
as history of MI,  PCI, or obstructive coronary artery disease. Left
ventricular ejection fraction (LVEF) was assessed using modiﬁed
Simpson’s biplane method taken by two-dimensional transthoracic
echocardiography.
Coronary intervention was  performed according to current
standard procedures. Prior to the intervention, all patients received
300 mg  aspirin, 300–600 mg  clopidogrel, and unfractionated or
low-molecular-weight heparin. Coronary angiography was per-
formed through femoral or radial artery. Heparin was infused
throughout the procedure to maintain an activated clotting time
of at least 250 s. The choice of ZES or EES and administration of gly-
coprotein IIb/IIIa-receptor blockers was left to the decision of each
operator. Angiographic success was  deﬁned as the achievement of
a minimum stenosis diameter reduction to less than 50% in the
presence of Thrombolysis In Myocardial Infarction (TIMI) grade 2
or 3 ﬂow without complications such as death or coronary artery
bypass grafting (CABG). After PCI, 100–300 mg/day aspirin was con-
tinued indeﬁnitely, and 75 mg/day of clopidogrel was  continued for
≥12 months according to guidelines.
The baseline clinical characteristics, laboratory ﬁndings, LVEF,
coronary angiographic ﬁndings including infarct-related artery and
lesion classiﬁcation by American College of Cardiology/American
Heart Association (ACC/AHA) classiﬁcation [16], medical treatment,
in-hospital mortality, major adverse cardiac events (MACE) includ-
ing all-cause death, cardiac death, non-fatal MI,  TLR, TVR, re-PCI,
and target lesion failure (TLF), and stent thrombosis at 1-year were
investigated in both groups. TLF was  deﬁned as the composite of
cardiac death, recurrent nonfatal MI,  or TLR. Stent thrombosis was
deﬁned according to the Academic Research Consortium (ARC) [17],
and reported separately for the early (0–30 days) and late (31–365
days) period. Early stent thrombosis was  classiﬁed as acute if it
occurred within 24 h and subacute if it occurred from 24 h to 30
days.
The primary endpoints were total MACE, cardiac death, and TLF
at 1-year follow-up. The secondary endpoint was stent thrombosis.
We performed subgroup analysis for MACE in patients who were
discharged alive, since the in-hospital mortality rate is relatively
high in AMI  patients.
Statistical analysis
The Statistical Package for Social Sciences (SPSS) for Windows
version 18.0 (SPSS-PC Inc., Chicago, IL, USA) was used for all anal-
yses. Continuous variables were presented as mean ± standard
deviation and were compared using Student’s t-test or non-
parametric Wilcoxon test if normality assumption was  violated.
Discrete variables were presented as counts and percentage,
and compared using Chi-square test or Fisher’s exact test, as
appropriate.
Propensity score was  obtained from logistic regression of the
covariates that were adjusted for the ZES and EES and included age,
gender, cardiovascular risk factors (hypertension, diabetes melli-
tus, hyperlipidemia, smoking, family history of CAD, prior ischemic
heart disease), Killip class, diagnosis, LVEF, multivessel disease,
infarct-related artery, lesion type, pre-PCI TIMI ﬂow grade, stent
length, use of glycoprotein IIb/IIIa inhibitor, use of intravascular
ultrasound (IVUS), and medical treatments. Then, patients treated
with ZES were 1-to-1 matched to the patients treated with EES.
Subjects were matched with a caliper width equal to 0.05 and 651
well-matched pairs were extracted.
Clinical outcomes at 1-year follow-up were estimated with
Kaplan–Meier survival curve, and the differences between the two
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atched patients. The Cox proportional hazard models were per-
ormed to assess the adjusted hazard ratio comparing the two
roups. Clinical signiﬁcance is deﬁned as p < 0.05.
able 1
aseline clinical and angiographic characteristics, and medical treatment.
Variables ZES (n = 651) 
Baseline clinical characteristics
Age (years) 68.8 ± 12.5
Male  (%) 392 (60.2) 
Past  history (%)
Hypertension 361 (55.5) 
Diabetes mellitus 207 (31.8) 
Smoking 350 (53.8) 
Hyperlipidemia 245 (37.6) 
Familial history of heart disease 48 (7.4) 
Prior  history of ischemic heart disease 81 (12.5) 
Symptoms and hemodynamic on admission
Systolic blood pressure (mmHg) 132.0 ± 29.4
Heart  rate (beats/min) 79.4 ± 16.6 
Killip  class 
I  467 (71.7) 
II  88 (13.5) 
III  65 (10.0) 
IV  31 (4.8) 
Diagnosis 
STEMI  (%) 338 (51.9) 
NSTEMI (%) 313 (48.1) 
Echocardiographic ﬁndings
LVEF (%) 52.0 ± 12.7 
Angiographic and procedural characteristics
Diseased vessels 
1  vessel 223 (34.3) 
2  vessels 228 (35.0) 
3  vessels 186 (28.6) 
Left  main, isolated 0 (0)
Left  main, complex 14 (2.2) 
Multivessel disease 414 (63.6) 
Multivessel PCI in multivessel disease 147/414 (35.5
Infarct-related artery 
Left  main 4 (0.6) 
Left  anterior descending artery 303 (46.5) 
Left  circumﬂex artery 181 (27.8) 
Right coronary artery 163 (25.0) 
Lesion typea
A  23 (3.5) 
B1  85 (13.1) 
B2  218 (33.5)
C  325 (49.9) 
Pre-PCI TIMI ﬂow grade 
0  299 (45.9) 
I  99 (15.2) 
II  123 (18.9) 
III  130 (20.2) 
Stent diameter 
2.75  mm 420 (64.5) 
2.50  mm 231 (35.5) 
Stent length (mm) 23.9 ± 6.8 
Glycoprotein IIb–IIIa receptor inhibitor use 64 (9.8) 
Use  of intravascular ultrasound 170 (18.0) 
Success of PCI 632 (97.1) 
Medical treatment
Aspirin 647 (99.4) 
Clopidogrel or ticlopidine 646 (99.2) 
Cilostazole 197 (30.3) 
Glycoprotein IIb–IIIa receptor inhibitor 48 (7.4) 
Uinfractionated heparin 369 (56.7) 
Low  molecular weight heparin 166 (25.5) 
Beta  blocker 503 (77.3) 
Calcium channel blockers 64 (9.8) 
Angiotensin-converting enzyme inhibitor 407 (62.5) 
Angiotensin II receptor blockers 134 (20.6) 
Statins 536 (82.3) 
a Lesion type according to American College of Cardiology/American Heart Association
eft  ventricular ejection fraction; NSTEMI, non ST-elevation myocardial infarction; PCI, per
hrombolysis in myocardial infarction.logy 63 (2014) 409–417 411Results
Although there were no signiﬁcant differences in baseline clini-
cal and angiographic characteristics between the two groups, there
EES (n = 914) p
67.4 ± 11.6 0.018
604 (66.1) 0.017
498 (54.5) 0.705
315 (34.5) 0.270
500 (54.7) 0.713
371 (40.6) 0.238
59 (6.5) 0.478
105 (11.5) 0.541
132.4 ± 28.5 0.801
79.9 ± 16.1 0.885
0.550
673 (73.6)
128 (14.0)
80 (8.8)
64 (4.1)
0.880
471 (51.5)
443 (48.5)
52.3 ± 11.9 0.676
0.194
228 (35.0)
273 (29.9)
268 (29.3)
1 (0.1)
18 (2.0)
541 (59.2) 0.078
) 185/541 (34.2) 0.673
0.987
5 (0.5)
419 (45.8)
255 (27.9)
235 (23.7)
0.114
30 (3.3)
156 (17.1)
315 (34.5)
413 (45.2)
0.004
421 (46.1)
119 (13.0)
131 (14.3)
243 (26.6)
0.110
625 (68.4)
289 (31.6)
24.0 ± 7.0 0.976
93 (10.2) 0.184
170 (18.6) 0.752
891 (97.5) 0.653
911 (99.7) 0.403
910 (99.6) 0.394
275 (30.1) 0.941
79 (8.6) 0.364
596 (65.2) 0.001
192 (21.0) 0.037
783 (85.7) <0.001
82 (9.0) 0.564
568 (62.1) 0.880
236 (25.8) 0.016
761 (83.3) 0.632
 classiﬁcation, EES, everolimus-eluting stent; ZES, zotarolimus-eluting stent; LVEF,
cutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TIMI,
4  Cardio
w
a
e
T
a
T
B
a
v
t12 S.C. Cho et al. / Journal of
as considerable imbalance in age, gender, pre-TIMI ﬂow grade,
nd medical treatments (Table 1). The proportion of ST segment
levation MI  (STEMI) and LVEF was similar between the two  groups.
he baseline clinical and angiographic characteristics were bal-
nced after propensity score matching (Table 2).
able 2
aseline clinical and angiographic characteristics, and medical treatment of propensity sc
Variables ZES (n = 651) 
Baseline clinical characteristics
Age (years) 68.8 ± 12.5
Male  (%) 392 (60.2) 
Past  history (%)
Hypertension 361 (55.5) 
Diabetes mellitus 207 (31.8) 
Smoking 350 (53.8) 
Hyperlipidemia 245 (67.6) 
Family history of heart disease 48 (7.4) 
Prior  history of ischemic heart disease 81 (12.4) 
Symptoms and hemodynamics on admission
Systolic blood pressure (mmHg) 132.0 ± 29.4 
Heart  rate (beats/min) 79.1 ± 19.8 
Killip  class 
I  467 (71.7) 
II  88 (13.5) 
III  65 (10.0) 
IV  31 (4.8)
Diagnosis 
STEMI (%) 338 (51.9) 
NSTEMI (%) 313 (48.1) 
Echocardiographic ﬁndings
LVEF (%) 52.0 ± 12.7 
Angiographic and procedural characteristics
Diseased vessels
1 vessel 223 (34.3) 
2  vessels 228 (35.0) 
3  vessels 186 (28.6) 
Left  main, isolated 0 
Left  main, complex 14 (2.2)
Multivessel disease 414 (63.6) 
Multivessel PCI in multivessel disease 147/414 (35.5) 
Infarct-related artery 
Left  main 4 (0.6) 
Left  anterior descending artery 303 (46.5) 
Left  circumﬂex artery 181 (27.8) 
Right coronary artery 163 (25.0)
Lesion typea
A  23 (3.5) 
B1  85 (13.1) 
B2  218 (33.5) 
C  325 (49.9) 
Pre-PCI TIMI ﬂow grade 
0  299 (45.9) 
I  99 (15.2) 
II  123 (18.9) 
III  130 (20.0) 
Stent diameter 
2.75  mm 420 (64.5) 
2.50  mm 231 (35.5) 
Stent length (mm) 23.8 ± 6.2 
Glycoprotein IIb–IIIa inhibitors use 64 (9.8) 
Use  of intravascular ultrasound 117 (18.0) 
Success of PCI 632 (97.1) 
Medical treatment
Aspirin 647 (99.4) 
Clopidogrel or ticlopidine 646 (99.2) 
Cilostazole 197 (30.3) 
Glycoprotein IIb-IIIa receptor inhibitors 48 (7.4) 
Unfractionated heparin 369 (56.7) 
Low  molecular weight heparin 166 (25.5) 
Beta  blocker 503 (77.3) 
Calcium channel blockers 64 (9.8) 
Angiotensin-converting enzyme inhibitor 407 (62.5)
Angiotensin II receptor blockers 134 (20.6) 
Statins 536 (82.3) 
Lesion type according to American College of Cardiology/American Heart Association cla
entricular ejection fraction; NSTEMI, non ST-elevation myocardial infarction; PCI, perc
hrombolysis in myocardial infarction.logy 63 (2014) 409–417
The 1-year clinical outcomes before and after propensity score
matching are summarized in Table 3. One-year cardiac death (5.4%
vs. 3.3%, p = 0.041), TLF (6.9% vs. 4.3%, p = 0.022), and stent thrombo-
sis (1.4% vs. 0.4%, p = 0.042), especially, subacute stent thrombosis
(0.5% vs. 0%, p = 0.018) were signiﬁcantly lower in the EES group
ore matched patients.
EES (n = 651) p
68.2 ± 11.8 0.359
409 (62.8) 0.333
354 (54.4) 0.697
212 (32.6) 0.767
362 (55.6) 0.504
247 (37.9) 0.909
44 (6.8) 0.665
81 (12.4) 1.000
132.2 ± 27.7 0.891
80.0 ± 19.6 0.513
0.835
476 (73.1)
89 (13.7)
61 (9.4)
25 (3.8)
0.657
330 (50.7)
321 (49.3)
52.0 ± 12.1 0.930
0.904
223 (34.3)
217 (33.3)
196 (30.1)
0
15 (2.3)
413 (63.4) 0.954
146/413 (35.4) 0.963
0.965
4 (0.6)
309 (47.5)
183 (28.1)
155 (23.8)
0.984
22 (3.4)
81 (12.4)
222 (34.1)
326 (50.1)
0.728
305 (46.9)
88 (13.5)
117 (18.0)
141 (21.7)
0.816
424 (65.1)
227 (34.9)
24.2 ± 7.1 0.333
62 (9.5) 0.851
115 (17.7) 0.885
634 (97.4) 0.515
648 (99.5) 0.705
647 (99.4) 0.738
209 (32.1) 0.473
49 (7.5) 0.916
385 (59.1) 0.369
155 (23.8) 0.479
530 (81.4) 0.065
62 (9.5) 0.851
412 (63.3) 0.774
132 (20.3) 0.891
539 (82.8) 0.827
ssiﬁcation, EES, everolimus-eluting stent; ZES, zotarolimus-eluting stent; LVEF, left
utaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TIMI,
S.C. Cho et al. / Journal of Cardiology 63 (2014) 409–417 413
Table  3
In-hospital and one year clinical outcomes before and after propensity score matching.
Variables Entire patients Propensity score-matched patients
ZES (n = 651) EES (n = 914) p ZES (n = 651) EES (n = 651) p
In-hospital outcomes
Total death 36 (5.5) 35 (3.8) 0.111 36 (5.5) 30 (4.6) 0.448
Cardiac death 30 (4.6) 26 (2.8) 0.064 30 (4.6) 21 (3.2) 0.199
Outcomes at 1 year
Total MACE 64 (9.8) 75 (8.2) 0.265 64 (9.8) 61 (9.4) 0.778
Total  death 43 (6.6) 48 (5.3) 0.259 43 (6.6) 39 (6.0) 0.648
Cardiac death 35 (5.4) 30 (3.3) 0.041 35 (5.4) 24 (3.7) 0.143
Non-fatal MI  6 (0.9) 3 (0.3) 0.126 6 (0.9) 3 (0.5) 0.316
Re-PCI 28 (2.8) 28 (3.1) 0.730 28 (2.8) 20 (3.1) 0.742
TLR  9 (1.4) 9 (1.0) 0.467 9 (1.4) 8 (1.2) 0.807
TVR  13 (2.0) 13 (1.4) 0.381 13 (2.0) 11 (1.7) 0.680
TLF  45 (6.9) 39 (4.3) 0.022 45 (6.9) 32 (4.9) 0.127
Probable or deﬁnite stent thrombosis 9 (1.4) 4 (0.4) 0.042 9 (1.4) 3 (0.5) 0.082
Acute 0 (0) 1 (0.1) 0.399 0 (0) 0 (0) 1.000
Subacute 4 (0.5) 0 (0) 0.018 4 (0.6) 0 (0) 0.045
Late  5 (0.8) 3 (0.3) 0.229 5 (0.8) 3 (0.5) 0.478
EES, everolimus-eluting stent; ZES, zotarolimus-eluting stent; MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary intervention; TLR,
target lesion revascularization; TVR, target-vessel revascularization; TLF, target lesion failure.
Table 4
One-year clinical outcomes before and after propensity score matching in patients who were discharged alive.
Variables Entire patients Propensity score-matched patients
ZES (n = 615) EES (n = 879) p ZES (n = 615) EES (n = 621) p
Outcomes at 1 year
Total MACE 29 (4.7) 40 (4.6) 0.881 29 (4.7) 31 (5.0) 0.821
Total  death 8 (1.3) 13 (1.5) 0.773 8 (1.3) 9 (1.4) 0.823
Cardiac death 6 (1.0) 4 (0.5) 0.225 6 (1.0) 3 (0.5) 0.309
Non-fatal MI  6 (1.0) 3 (0.3) 0.119 6 (1.0) 3 (0.5) 0.309
Re-PCI 18 (2.9) 28 (3.2) 0.776 18 (2.9) 20 (3.2) 0.765
TLR  9 (1.5) 9 (1.0) 0.443 9 (1.5) 8 (1.3) 0.791
TVR  13 (2.1) 13 (1.5) 0.356 13 (2.1) 11 (1.8) 0.663
TLF  16 (2.6) 13 (1.5) 0.122 16 (2.6) 11 (1.8) 0.318
Probable or deﬁnite stent thrombosis 8 (1.3) 4 (0.5) 0.071 8 (1.3) 3 (0.5) 0.126
Acute 0 (0) 1 (0.1) 0.403 0 (0) 0 (0) 1.000
Subacute 3 (0.5) 0 (0) 0.038 3 (0.5) 0 (0) 0.081
Late  5 (0.8) 3 (0.3) 0.219 5 (0.8) 3 (0.5) 0.470
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han in the ZES group. However, 1-year total MACE were not
igniﬁcantly different between the two groups.
After propensity score matched analysis, major clinical out-
omes at one year including in-hospital death, total MACE, re-PCI,
LR, TVR, and TLF were not signiﬁcantly different between the two
roups, although stent thrombosis tended to be lower and subacute
tent thrombosis (0.6% vs. 0%, p = 0.045) was signiﬁcantly lower in
he EES group. There were no differences in clinical outcomes in
ubgroup analysis for patients discharged alive before and after
ropensity score matching (Table 4).
Figs. 1 and 2 show Kaplan–Meier curves for various clinical out-
omes in the total patient population and the patients discharged
live at 1-year in the propensity score matched patients. And,
able 5 shows adjusted hazard ratios for various clinical outcomes
ssociated with EES compared with ZES. Variables for multivari-
ble Cox proportional hazard models included stent types (ZES vs.
ES), age, gender, cardiovascular risk factors (hypertension, dia-
etes mellitus, hyperlipidemia, smoking, family history of CAD,
rior ischemic heart disease), Killip class, diagnosis (STEMI vs.
on-STEMI), LVEF < 40%, multivessel disease, infarct-related artery,
esion type, pre-PCI TIMI ﬂow grade, stent length, use of glycopro-
ein IIb/IIIa inhibitor, use of IVUS, and medical treatment. Adjusted
azard ratios for all clinical outcomes had no statistical signiﬁcance.
he type of stents, EES or ZES, did not predict the 1-year clinical
utcomes except subacute stent thrombosis.ac events; MI, myocardial infarction; PCI, percutaneous coronary intervention; TLR,
lure.
Discussion
In the total patient population, 1-year total MACE were not sig-
niﬁcantly different between the two groups despite signiﬁcantly
lower rates of cardiac death, TLF, and stent thrombosis in the EES
group. We  consider that the overlap of variable clinical outcomes
resulted in no signiﬁcant difference in total MACE.
Propensity score matched analysis demonstrated that AMI
patients treated with ZES and EES for small vessel disease are com-
parable in 1-year clinical outcomes including total MACE, cardiac
death, re-PCI, TLR, TVR, and TLF. Stent thrombosis tended to be
lower and subacute stent thrombosis was signiﬁcantly lower with
EES compared with ZES.
Recent studies demonstrated that ZES was non-inferior to EES
in clinical and angiographic outcomes [18–22]. There were no
signiﬁcant differences in the hard endpoints of death or MI  at
24 months between propensity-matched 3286 patients who
received EES versus those who received Endeavor-ZES. However,
patients with EES experienced lower rates of TLR and TVR than
patients with Endeavor-ZES [18].
The RESOLUTE ALL Comers Trial, multicenter and random-
ized trial compared two  new generation drug-eluting stents: the
Resolute-ZES and the Xience V-EES. Randomly assigned 2292
patients who underwent PCI with ZES (1140 patients) or EES
(1152 patients) with minimal exclusion criteria were enrolled. The
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Fig. 1. Kaplan–Meier survival curves describing cumulative incidences of 1-year clinical outcomes in propensity score matched patients. EES, everolimus-eluting stent; ZES,
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potarolimus-eluting stent.
xclusion criteria were a known intolerance to a study drug,
etal alloys, or contrast media; planned surgery within 6 months
fter the index procedure; childbearing potential; and partici-
ation in another trial before reaching the primary end point.
t 13-month follow-up, ZES was non-inferior to the EES in the
SR (21.65 ± 14.42% ZES vs. 19.76 ± 14.64% EES, p = 0.04 for non-
nferiority), late lumen loss (0.27 ± 0.43 mm vs. 0.19 ± 0.40 mm, = 0.08), and adverse events [17]. The 2-year follow-up result of
ESOLUTE All Comers Trial revealed similar safety and efﬁcacy
utcomes. The patient-related outcome (20.6% ZES vs. 20.5% EES,
 = 0.958) and stent-related outcome (11.2% vs. 10.74%, p = 0.736)did not differ between the two  groups [20]. MACE were more fre-
quent among complex patients who  had AMI  within 72 h, LVEF
<30%, treatment of bifurcation lesion, saphenous vein grafts, arte-
rial grafts, ISR, un-protected left main lesion, more than 2 vessels
treated, lesion length >27 mm,  more than 1 lesion/vessel, lesions
with thrombus, or lesions with total occlusion. However, results
did not differ between ZES (764 patients) and EES (756 patients),
regardless of complexity, with similar clinical and angiographic
outcomes at 1-year follow-up [21].
The TWENTE Trial was a randomized non-inferiority study with
limited exclusion criteria (acute STEMI not eligible) for patients
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Big. 2. Kaplan–Meier survival curves describing cumulative incidences of 1-year cl
luting  stent; ZES, zotarolimus-eluting stent.
andomly assigned to Resolute ZES (697 patients) or Xience V EES
694 patients). The primary composite end points of target vessel
ailure were similar between the two groups. Additionally, there
as no signiﬁcant difference in the individual components of the
rimary endpoints (cardiac death, target vessel-related MI,  and
linically indicated TVR) [22].
Recently, Bangalore et al. reported a meta-analysis of ran-
omized trials for 117,762 patient-years [23]. Compared with
MS, there was signiﬁcant reduction in MI  with all DES except
aclitaxel-eluting stent (PES). PES was inferior compared with
irolimus-eluting stent (SES), ZES, and EES. And compared with
MS, there was no increase in any stent thrombosis with any DES.outcomes in propensity score matched patients discharged alive. EES, everolimus-
For the between-DES comparisons, EES decreased any stent throm-
bosis compared with SES, PES, and ZES. In conclusion, there were
considerable differences among the DES types, such that EES, SES,
and Resolute ZES were the most efﬁcacious and EES was  the safest
stent. In a recent study of KAMIR, Chen et al. compared EES and ZES
in patients with AMI  and reported that EES was superior to ZES in
reducing TLF and stent thrombosis. Despite similar incidences of
recurrent nonfatal MI,  in-hospital and one-year mortality, patients
in the EES group had signiﬁcantly lower rates of TLF (6.5% vs. 8.7%,
p = 0.029) and probable or deﬁnite stent thrombosis (0.3% vs. 1.6%,
p < 0.001) [24]. The present study also showed no signiﬁcant dif-
ference in composite MACE at one-year. Although there were no
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Table  5
Multivariable adjusted hazard ratio of EES compared with ZES in propensity score
matched patients and the patients who were discharged alive among them.
Variables HR 95% CI p
Propensity score matched patients
In-hospital outcomes
Total death 0.926 0.564–1.520 0.762
Cardiac death 0.737 0.419–1.297 0.290
Clinical outcomes at 1 year
Total MACE 0.998 0.700–1.423 0.993
Total death 0.952 0.614–1.476 0.824
Cardiac death 0.724 0.428–1.226 0.230
Non-fatal MI 0.462 0.141–1.511 0.202
Re-PCI 1.032 0.566–1.883 0.917
TLR  0.810 0.348–1.881 0.623
TVR  0.792 0.380–1.652 0.534
TLF  0.742 0.479–1.150 0.182
Probable or deﬁnite stent thrombosis 0.474 0.164–1.374 0.169
Patients Discharged Alive
Total MACE 1.060 0.638–1.762 0.822
Total death 1.238 0.719–2.132 0.442
Cardiac death 0.560 0.133–2.279 0.410
Non-fatal MI  0.505 0.151–1.693 0.268
Re-PCI 1.030 0.565–1.879 0.922
TLR  0.807 0.347–1.877 0.619
TVR  0.790 0.379–1.647 0.529
TLF  0.696 0.350–1.384 0.302
Probable or deﬁnite stent thrombosis 0.505 0.171–1.494 0.217
EES, everolimus-eluting stent; ZES, zotarolimus-eluting stent; MACE, major adverse
cardiac event; MI,  myocardial infarction; PCI, percutaneous coronary intervention;
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eluting or bare-metal stent implantation in small coronary arteries. J CardiolLF, target lesion failure; TLR, target lesion revascularization; TVR, target vessel
evascularization.
tatistical differences, EES tended to reduce stent thrombosis, espe-
ially subcute stent thrombosis.
The SPIRIT trials demonstrated that the EES was superior to
ES in angiographic and clinical outcomes in patients with small
AD [25–27]. However, there is a paucity of data directly com-
aring EES and ZES in small CAD. Hong et al. demonstrated that
ES reduced the rate of MACE when compared with SES, PES, and
ES, mainly due to the lower rate of TLR. They compared angiog-
aphic and clinical outcomes in stable angina patients with SES,
ES, ZES, and EES implantation in small coronary target vessels
reference vessel diameter <2.75 mm)  and long lesions (lesion
ength ≥28 mm).  Late loss (EES 0.34 ± 0.14 mm,  PES 0.60 ± 0.15 mm,
nd ZES 0.65 ± 0.16 mm,  p < 0.05), rate of TLR (EES 2.1%, SES 9.8%,
ES 11.8%, and ZES 8.4%), and rate of MACE were signiﬁcant in the
ES during the 3-year follow-up [28].
The incidence of stent thrombosis (1.5% vs. 0.5%, p = 0.082)
ended to be lower, especially, subacute stent thrombosis (0.7%
s. 0%, p = 0.045) was signiﬁcantly lower in EES group. A pre-
ious study showed low incidence of stent thrombosis in EES
ompared with other DES. In the results from the SPIRIT III and
PRIT IV trials, incidence of stent thrombosis at 1 year was 0.2% in
atients with EES for small vessel disease [27]. A meta-analysis by
aber et al. reported that EES signiﬁcantly reduced stent throm-
osis (relative risk 0.55, 95% CI 0.38–0.78, p = 0.001) compared
ith non-everolimus-eluting DES [29]. Although, recent ongoing
tudies are assessing the value of shorter or longer duration of
2Y12 inhibitor administration, current guidelines recommended
hat a dual antiplatelet therapy should be administered for at least
2 months in clinical practice [30].
Recent studies about DES have tendency of comparing one DES
gainst all other DES [31], and direct comparisons of two DES have
een limited. Moreover, there were limited data about compari-
on of ZES and EES in AMI  patients with small CAD. The present
tudy performed a retrospective analysis in AMI  patients who were
reated with ZES or EES for small CAD in the “real-world” KAMIR-
egistry. The incidences of clinical outcomes at 1-year follow-up
[logy 63 (2014) 409–417
were not signiﬁcantly different between ZES and EES. These were
the same as subgroup analysis.
Study limitations
The present study had some limitations. First, the study is ret-
rospective and non-randomized using registry data and enrolled
patients had AMI. And, it was  subject to the limitations pertinent
to this type of clinical investigation. We conducted propensity score
matched analysis and used Cox proportional hazard model to min-
imize the selection bias. Second, small CAD was deﬁned as stent
diameter ≤2.75 mm because quantitative coronary angiography
(QCA) and IVUS were performed in a limited number of patients.
Third, the present study did not include angiographic outcomes
because routine angiographic follow up was not performed.
Conclusion
In the present propensity score matched analysis, ZES and EES
showed no signiﬁcant difference in 1-year clinical outcomes in
patients with AMI  of small CAD (stent diameter ≤2.75 mm)  in “real
world” practice. Further randomized studies are needed to conﬁrm
these results.
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